These are 2023′s Mass. college and university commencement speakers
Find out some of the famous faces coming to Massachusetts colleges and universities this spring for graduation season.
Source: masslive.com
Quercis Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Quercis Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Quercis Pharma Today - Breaking & Trending Today
DelveInsight Business Research, LLP: Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment
COVID-19 clinical trial pipeline constitutes 420+ key companies continuously working towards developing 520+ COVID-19 vaccines and drugs, analyzes DelveInsight LAS VEGAS, Nov. 8, 2022 /PRNewswire/
Source: finanznachrichten.de
Global COVID-19 Pipeline Report 2021 - Comprehensive Insights About 400+ Companies and 400+ Pipeline Drugs
/PRNewswire/ -- The "COVID-19 - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. This "COVID-19 - Pipeline Insight,...
Source: prnewswire.com
Western New England University and Quercis Pharma Sign Exclusive Worldwide License Agreements
SPRINGFIELD, Mass. and ZUG, Switzerland, May 19, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company, has signed a worldwide license agreement with...
Source: marketscreener.com
Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration
Share this article Share this article ZUG, Switzerland, May 4, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces that it has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the protocol titled, "A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3)." Isoquercetin, the Company's le...
Source: prnewswire.com